Ask AI
ProCE Banner Activity

CE

Myth vs Medicine: Pharmacist’s Perspective on Adjuvant CDK4/6 Inhibitor Optimization

Podcast Episodes

Listen to oncology pharmacists, Julia L. Ziegengeist, PharmD, BCOP, and Rodney Hunter, PharmD, BCOP, discuss assumptions about adjuvant CDK4/6 inhibitor use in high-risk HR+/HER2- early breast cancer, providing their experiences using these therapies for their patients with early-stage breast cancer.

Pharmacists: 1.00 contact hour (0.1 CEUs)

Released: March 13, 2026

Expiration: March 12, 2027

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from Lilly.

Lilly

Target Audience

This activity is intended for oncology pharmacists and other healthcare professionals involved in the management of patients with high-risk HR-positive, HER2-negative EBC.

Program Learning Goal

The activity aims to improve learners’ knowledge, competence, and confidence in translating evolving adjuvant CDK4/6 inhibitor evidence into consistent, high-quality practice in the management of patients with high-risk HR-positive, HER2-negative EBC.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Interpret key efficacy endpoints, including IDFS and OS, from pivotal adjuvant CDK4/6 inhibitor trials and apply these data to appropriate, guideline-aligned use in high-risk HR+/HER2- EBC 

  • Implement evidence-based, pharmacist-led strategies to support patient selection and personalization of adjuvant CDK4/6 inhibitor therapy, incorporating individual risk factors, treatment goals, and regimen duration 

  • Proactively identify, monitor, and manage treatment-related toxicities, including appropriate dose modification strategies, to maintain therapeutic intent while supporting adherence and persistence with long-duration oral therapy 

  • Apply effective patient and multidisciplinary communication approaches to reinforce adherence, persistence, and shared decision-making throughout the adjuvant CDK4/6 treatment course 

Disclosure

Decera Clinical Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to Decera Clinical Education policy. Decera Clinical Education is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Rodney Hunter, PharmD, BCOP: consultant/advisor/speaker: Lilly Oncology.

Julia L. Ziegengeist, PharmD, BCOP, has no relevant financial relationships to disclose.

The planners and content peer reviewers from Decera Clinical Education do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hour. To successfully complete this activity and receive credit, participants must follow these steps during the period from March 13, 2026, through March 12, 2027:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC dba Decera Clinical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Continuing Pharmacy Education

Clinical Care Options, LLC dba Decera Clinical Education designates this continuing education activity for 1 contact hour (0.10 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number: xxxx

Type of Activity: xxxx

Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.